- Home
- SPRO vs LNSR Comparison
SPRO vs LNSR Comparison
Compare SPRO & LNSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- LNSR
- Stock Information
- Founded
- SPRO 2013
- LNSR 2004
- Country
- SPRO United States
- LNSR United States
- Employees
- SPRO N/A
- LNSR N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- LNSR Medical Electronics
- Sector
- SPRO Health Care
- LNSR Health Care
- Exchange
- SPRO Nasdaq
- LNSR Nasdaq
- Market Cap
- SPRO 136.7M
- LNSR 142.0M
- IPO Year
- SPRO 2017
- LNSR N/A
- Fundamental
- Price
- SPRO $2.24
- LNSR $9.70
- Analyst Decision
- SPRO Buy
- LNSR Hold
- Analyst Count
- SPRO 2
- LNSR 1
- Target Price
- SPRO $5.00
- LNSR $15.00
- AVG Volume (30 Days)
- SPRO 504.7K
- LNSR 74.4K
- Earning Date
- SPRO 11-13-2025
- LNSR 11-06-2025
- Dividend Yield
- SPRO N/A
- LNSR N/A
- EPS Growth
- SPRO N/A
- LNSR N/A
- EPS
- SPRO N/A
- LNSR N/A
- Revenue
- SPRO $40,549,000.00
- LNSR $59,141,000.00
- Revenue This Year
- SPRO N/A
- LNSR $30.80
- Revenue Next Year
- SPRO N/A
- LNSR $33.09
- P/E Ratio
- SPRO N/A
- LNSR N/A
- Revenue Growth
- SPRO N/A
- LNSR 21.02
- 52 Week Low
- SPRO $0.51
- LNSR $7.00
- 52 Week High
- SPRO $3.22
- LNSR $17.31
- Technical
- Relative Strength Index (RSI)
- SPRO 43.25
- LNSR 27.78
- Support Level
- SPRO $2.33
- LNSR $9.46
- Resistance Level
- SPRO $2.57
- LNSR $10.48
- Average True Range (ATR)
- SPRO 0.15
- LNSR 0.56
- MACD
- SPRO -0.03
- LNSR -0.14
- Stochastic Oscillator
- SPRO 0.00
- LNSR 6.81
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About LNSR LENSAR Inc.
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.